Our team investigates how timed modulation of the cGAS/STING pathway can improve outcomes after allogeneic stem cell transplantation by reducing GvHD while preserving or enhancing GvL. Building on our prior findings, we will collaboratively define optimal pharmacological and microbiota-based strategies using preclinical models, in vitro systems, and single-cell multi-omics. Together, we aim to develop a precision-medicine approach that achieves durable anti-tumor immunity with minimal toxicity.

I’m a Professor of Medicine in Regensburg specializing in immunotherapy and cancer research. My work focuses on innate immunity and microbiome interactions, including their role in stem cell transplantation and CAR T-cell therapy